Supernus Pharmaceuticals (SUPN) Retained Earnings (2011 - 2026)
Supernus Pharmaceuticals (SUPN) reported Retained Earnings of $515.6 million for Q1 2026, up 324366.04% year-over-year from N/an in Q1 2025, and up 1171879.55% quarter-over-quarter from -$44000.0 in Q4 2025.
Supernus Pharmaceuticals (SUPN) Retained Earnings (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 16 years of Retained Earnings data on file, last reported at $515.6 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at $515.6 million, up 324366.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $515.6 million (up 324366.04% YoY), and the FY2025 annual result was -$44000.0, up 76.72% from the prior year.
- Retained Earnings grew to $515.6 million in Q1 2026 per SUPN's latest filing, from -$44000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $515.6 million in Q1 2026 and troughed at -$3.2 million in Q4 2022.
- A 5-year average of $197.2 million and a median of -$44000.0 in 2025 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings plunged 308.58% in 2022, then jumped 324366.04% in 2026.
- A 5-year view of Retained Earnings shows it stood at -$3.2 million in 2022, then surged by 15133.05% to $482.6 million in 2023, then sank by 100.04% to -$189000.0 in 2024, then surged by 76.72% to -$44000.0 in 2025, then surged by 1171879.55% to $515.6 million in 2026.
- Business Quant data shows SUPN's Retained Earnings at $515.6 million in Q1 2026, -$44000.0 in Q4 2025, and -$71000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | -2.51 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | -772.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -10.20 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 683,383.23 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 589.60 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | -2.13 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -2.91 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | -1.87 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -4.41 Mn |
| 10 | Supernus Pharmaceuticals | 2.57 Bn | 2.19 Bn | - | 515.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 515.58 Mn |
| Dec 31, 2025 | -44,000.00 |
| Sep 30, 2025 | -71,000.00 |
| Jun 30, 2025 | -200,000.00 |
| Mar 31, 2025 | -159,000.00 |
| Dec 31, 2024 | -189,000.00 |
| Sep 30, 2024 | 78,000.00 |
| Jun 30, 2024 | -372,000.00 |
| Mar 31, 2024 | 482.69 Mn |
| Dec 31, 2023 | 482.56 Mn |
| Sep 30, 2023 | 481.39 Mn |
| Jun 30, 2023 | 497.36 Mn |
| Mar 31, 2023 | -2.33 Mn |
| Dec 31, 2022 | -3.21 Mn |
| Sep 30, 2022 | 455.76 Mn |
| Jun 30, 2022 | -2.22 Mn |
| Mar 31, 2022 | 446.15 Mn |
| Dec 31, 2021 | 1.54 Mn |
| Sep 30, 2021 | 377.48 Mn |
| Jun 30, 2021 | 355.92 Mn |